Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for AI-induced osteoporosis in postmenopausal early breast cancer
jRCT1061210010Active, not recruiting
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of zoledronic acid in osteoporosis and breast cancer. Primary endpoint: 3-year rate of bone density change. Started Jul 2021; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisbreast cancer
Beyond the preview
Go deeper on jRCT1061210010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061210010.